Life Science Instrumentation Market

Executive Summary

Life Science Instrumentation Market was valued at US $64.28 billion in 2021 and is projected to grow at 5.64% CAGR over the forecast period to reach US $89.33 billion by 2027. Life Science Instrumentation Market represented US $6.68 billion opportunity over 2019-2021 and estimated to create US $25.05 billion opportunity in 2027 over 2021.

Life Science Instrumentation from Consainsights analyses the Life Science Instrumentation Market in the Life Sciences industry over the forecast period to 2027.

Life Science Instrumentation research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Life Science Instrumentation segmentation includes Technology, Application, End-user, Region and Geography.

Based on the Technology, the Life Science Instrumentation analysis covers Spectroscopy, Chromatography, PCR, Immunoassays, Lyophilization, Liquid Handling, Clinical Chemistry Analyzers, Microscopy, Flow Cytometry, Next-Generation Sequencing (Ngs), Centrifuges, Electrophoresis, Cell Counting, Other Technologies.

In Technology segment, Spectroscopy segment has highest cagr growth of 5.00%.

Based on the Application, the Life Science Instrumentation analysis covers Research Applications, Clinical & Diagnostic Applications, Other Applications.

In Application segment, Research Applications segment has highest cagr growth of 5.00%.

Based on the End-user, the Life Science Instrumentation analysis covers Hospitals and Diagnostic Laboratories, Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Agriculture & Food Industries, Environmental Testing Labs, Clinical Research Organizations, Other End-users.

In End-user segment, Hospitals and Diagnostic Laboratories segment has highest cagr growth of 5.00%.

Based on the Region, the Life Science Instrumentation analysis covers North America, Europe, Asia-Pacific, Latin America, Middle East & Africa.

In Region segment, North America segment has highest cagr growth of 5.00%.

Based on the region, the Life Science Instrumentation analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include Agilent Technologies, Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Bruker Corporation, Danaher Corporation, Eppendorf AG, GE Healthcare, Hitachi High-Technologies Corporation, Horiba Ltd., Merck KGAA, Perkinelmer, Inc., Qiagen N.V., Shimadzu Corporation, Thermo Fisher Scientific, Inc., Waters Corporation, Other Companies and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Technology

Introduction

In 2021, Spectroscopy segment has the highest revenue of US $24.52 billion and is expected to grow at CAGR of 5.00% by 2027 Spectroscopy segment has highest cagr growth of 5.00%.

Spectroscopy

Spectroscopy segment was valued at US $21.97 billion in 2019 and is projected to grow at 5.00% CAGR over the forecast period to reach US $34.07 billion by 2027. Spectroscopy segment represented US $2.55 billion opportunity over 2019-2021 and estimated to create US $9.55 billion opportunity in 2027 over 2021.

Chromatography

Chromatography segment was valued at US $13.62 billion in 2019 and is projected to grow at 5.00% CAGR over the forecast period to reach US $21.12 billion by 2027. Chromatography segment represented US $1.58 billion opportunity over 2019-2021 and estimated to create US $5.92 billion opportunity in 2027 over 2021.

PCR

PCR segment was valued at US $8.43 billion in 2019 and is projected to grow at 5.00% CAGR over the forecast period to reach US $13.08 billion by 2027. PCR segment represented US $0.98 billion opportunity over 2019-2021 and estimated to create US $3.67 billion opportunity in 2027 over 2021.

Immunoassays

Immunoassays segment was valued at US $5.23 billion in 2019 and is projected to grow at 5.00% CAGR over the forecast period to reach US $8.11 billion by 2027. Immunoassays segment represented US $0.61 billion opportunity over 2019-2021 and estimated to create US $2.27 billion opportunity in 2027 over 2021.

Lyophilization

Lyophilization segment was valued at US $3.22 billion in 2019 and is projected to grow at 5.00% CAGR over the forecast period to reach US $5.00 billion by 2027. Lyophilization segment represented US $0.37 billion opportunity over 2019-2021 and estimated to create US $1.40 billion opportunity in 2027 over 2021.

Liquid Handling

Liquid Handling segment was valued at US $1.96 billion in 2019 and is projected to grow at 5.00% CAGR over the forecast period to reach US $3.04 billion by 2027. Liquid Handling segment represented US $0.23 billion opportunity over 2019-2021 and estimated to create US $0.85 billion opportunity in 2027 over 2021.

Clinical Chemistry Analyzers

Clinical Chemistry Analyzers segment was valued at US $1.21 billion in 2019 and is projected to grow at 5.00% CAGR over the forecast period to reach US $1.88 billion by 2027. Clinical Chemistry Analyzers segment represented US $0.14 billion opportunity over 2019-2021 and estimated to create US $0.53 billion opportunity in 2027 over 2021.

Microscopy

Microscopy segment was valued at US $0.72 billion in 2019 and is projected to grow at 5.00% CAGR over the forecast period to reach US $1.12 billion by 2027. Microscopy segment represented US $0.08 billion opportunity over 2019-2021 and estimated to create US $0.31 billion opportunity in 2027 over 2021.

Flow Cytometry

Flow Cytometry segment was valued at US $0.49 billion in 2019 and is projected to grow at 5.00% CAGR over the forecast period to reach US $0.76 billion by 2027. Flow Cytometry segment represented US $0.06 billion opportunity over 2019-2021 and estimated to create US $0.21 billion opportunity in 2027 over 2021.

Next-Generation Sequencing (Ngs)

Next-Generation Sequencing (Ngs) segment was valued at US $0.31 billion in 2019 and is projected to grow at 5.00% CAGR over the forecast period to reach US $0.48 billion by 2027. Next-Generation Sequencing (Ngs) segment represented US $0.04 billion opportunity over 2019-2021 and estimated to create US $0.13 billion opportunity in 2027 over 2021.

Centrifuges

Centrifuges segment was valued at US $0.18 billion in 2019 and is projected to grow at 5.00% CAGR over the forecast period to reach US $0.28 billion by 2027. Centrifuges segment represented US $0.02 billion opportunity over 2019-2021 and estimated to create US $0.08 billion opportunity in 2027 over 2021.

Electrophoresis

Electrophoresis segment was valued at US $0.11 billion in 2019 and is projected to grow at 5.00% CAGR over the forecast period to reach US $0.17 billion by 2027. Electrophoresis segment represented US $0.01 billion opportunity over 2019-2021 and estimated to create US $0.05 billion opportunity in 2027 over 2021.

Cell Counting

Cell Counting segment was valued at US $0.08 billion in 2019 and is projected to grow at 5.00% CAGR over the forecast period to reach US $0.13 billion by 2027. Cell Counting segment represented US $0.01 billion opportunity over 2019-2021 and estimated to create US $0.04 billion opportunity in 2027 over 2021.

Other Technologies

Other Technologies segment was valued at US $0.07 billion in 2019 and is projected to grow at 5.00% CAGR over the forecast period to reach US $0.10 billion by 2027. Other Technologies segment represented US $0.01 billion opportunity over 2019-2021 and estimated to create US $0.03 billion opportunity in 2027 over 2021.

Application

Introduction

In 2021, Research Applications segment has the highest revenue of US $29.37 billion and is expected to grow at CAGR of 5.00% by 2027 Research Applications segment has highest cagr growth of 5.00%.

Research Applications

Research Applications segment was valued at US $26.32 billion in 2019 and is projected to grow at 5.00% CAGR over the forecast period to reach US $40.82 billion by 2027. Research Applications segment represented US $3.05 billion opportunity over 2019-2021 and estimated to create US $11.45 billion opportunity in 2027 over 2021.

Clinical & Diagnostic Applications

Clinical & Diagnostic Applications segment was valued at US $15.53 billion in 2019 and is projected to grow at 5.00% CAGR over the forecast period to reach US $24.08 billion by 2027. Clinical & Diagnostic Applications segment represented US $1.80 billion opportunity over 2019-2021 and estimated to create US $6.75 billion opportunity in 2027 over 2021.

Other Applications

Other Applications segment was valued at US $15.75 billion in 2019 and is projected to grow at 5.00% CAGR over the forecast period to reach US $24.43 billion by 2027. Other Applications segment represented US $1.83 billion opportunity over 2019-2021 and estimated to create US $6.85 billion opportunity in 2027 over 2021.

End-user

Introduction

In 2021, Hospitals and Diagnostic Laboratories segment has the highest revenue of US $25.37 billion and is expected to grow at CAGR of 5.00% by 2027 Hospitals and Diagnostic Laboratories segment has highest cagr growth of 5.00%.

Hospitals and Diagnostic Laboratories

Hospitals and Diagnostic Laboratories segment was valued at US $22.73 billion in 2019 and is projected to grow at 5.00% CAGR over the forecast period to reach US $35.25 billion by 2027. Hospitals and Diagnostic Laboratories segment represented US $2.64 billion opportunity over 2019-2021 and estimated to create US $9.89 billion opportunity in 2027 over 2021.

Pharmaceutical and Biotechnology Companies

Pharmaceutical and Biotechnology Companies segment was valued at US $13.48 billion in 2019 and is projected to grow at 5.00% CAGR over the forecast period to reach US $20.90 billion by 2027. Pharmaceutical and Biotechnology Companies segment represented US $1.56 billion opportunity over 2019-2021 and estimated to create US $5.86 billion opportunity in 2027 over 2021.

Academic and Research Institutes

Academic and Research Institutes segment was valued at US $8.01 billion in 2019 and is projected to grow at 5.00% CAGR over the forecast period to reach US $12.42 billion by 2027. Academic and Research Institutes segment represented US $0.93 billion opportunity over 2019-2021 and estimated to create US $3.48 billion opportunity in 2027 over 2021.

Agriculture & Food Industries

Agriculture & Food Industries segment was valued at US $6.27 billion in 2019 and is projected to grow at 5.00% CAGR over the forecast period to reach US $9.73 billion by 2027. Agriculture & Food Industries segment represented US $0.73 billion opportunity over 2019-2021 and estimated to create US $2.73 billion opportunity in 2027 over 2021.

Environmental Testing Labs

Environmental Testing Labs segment was valued at US $3.81 billion in 2019 and is projected to grow at 5.00% CAGR over the forecast period to reach US $5.90 billion by 2027. Environmental Testing Labs segment represented US $0.44 billion opportunity over 2019-2021 and estimated to create US $1.66 billion opportunity in 2027 over 2021.

Clinical Research Organizations

Clinical Research Organizations segment was valued at US $1.18 billion in 2019 and is projected to grow at 5.00% CAGR over the forecast period to reach US $1.83 billion by 2027. Clinical Research Organizations segment represented US $0.14 billion opportunity over 2019-2021 and estimated to create US $0.51 billion opportunity in 2027 over 2021.

Other End-users

Other End-users segment was valued at US $2.12 billion in 2019 and is projected to grow at 5.00% CAGR over the forecast period to reach US $3.29 billion by 2027. Other End-users segment represented US $0.25 billion opportunity over 2019-2021 and estimated to create US $0.92 billion opportunity in 2027 over 2021.

Region

Introduction

In 2021, North America segment has the highest revenue of US $28.20 billion and is expected to grow at CAGR of 5.00% by 2027 North America segment has highest cagr growth of 5.00%.

North America

North America segment was valued at US $25.27 billion in 2019 and is projected to grow at 5.00% CAGR over the forecast period to reach US $39.19 billion by 2027. North America segment represented US $2.93 billion opportunity over 2019-2021 and estimated to create US $10.99 billion opportunity in 2027 over 2021.

Europe

Europe segment was valued at US $15.34 billion in 2019 and is projected to grow at 5.00% CAGR over the forecast period to reach US $23.79 billion by 2027. Europe segment represented US $1.78 billion opportunity over 2019-2021 and estimated to create US $6.67 billion opportunity in 2027 over 2021.

Asia-Pacific

Asia-Pacific segment was valued at US $6.16 billion in 2019 and is projected to grow at 5.00% CAGR over the forecast period to reach US $9.55 billion by 2027. Asia-Pacific segment represented US $0.71 billion opportunity over 2019-2021 and estimated to create US $2.68 billion opportunity in 2027 over 2021.

Latin America

Latin America segment was valued at US $6.60 billion in 2019 and is projected to grow at 5.00% CAGR over the forecast period to reach US $10.23 billion by 2027. Latin America segment represented US $0.76 billion opportunity over 2019-2021 and estimated to create US $2.87 billion opportunity in 2027 over 2021.

Middle East & Africa

Middle East & Africa segment was valued at US $4.24 billion in 2019 and is projected to grow at 5.00% CAGR over the forecast period to reach US $6.57 billion by 2027. Middle East & Africa segment represented US $0.49 billion opportunity over 2019-2021 and estimated to create US $1.84 billion opportunity in 2027 over 2021.